tetano
Editor, Senior Moderator
NPJ Vaccines
. 2022 Jul 29;7(1):85.
doi: 10.1038/s41541-022-00509-6.
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2
Mariana F Tioni[SUP] #[/SUP][SUP] 1 [/SUP], Robert Jordan[SUP] #[/SUP][SUP] 2 3 [/SUP], Angie Silva Pena[SUP] 2 [/SUP], Aditya Garg[SUP] 2 [/SUP], Danlu Wu[SUP] 2 [/SUP], Shannon I Phan[SUP] 2 [/SUP], Christopher M Weiss[SUP] 2 [/SUP], Xing Cheng[SUP] 2 [/SUP], Jack Greenhouse[SUP] 4 [/SUP], Tatyana Orekov[SUP] 4 [/SUP], Daniel Valentin[SUP] 4 [/SUP], Swagata Kar[SUP] 4 [/SUP], Laurent Pessaint[SUP] 4 [/SUP], Hanne Andersen[SUP] 4 [/SUP], Christopher C Stobart[SUP] 5 [/SUP], Melissa H Bloodworth[SUP] 6 [/SUP], R Stokes Peebles[SUP] 6 7 [/SUP], Yang Liu[SUP] 8 [/SUP], Xuping Xie[SUP] 8 [/SUP], Pei-Yong Shi[SUP] 8 [/SUP], Martin L Moore[SUP] 2 [/SUP], Roderick S Tang[SUP] 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine.
. 2022 Jul 29;7(1):85.
doi: 10.1038/s41541-022-00509-6.
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2
Mariana F Tioni[SUP] #[/SUP][SUP] 1 [/SUP], Robert Jordan[SUP] #[/SUP][SUP] 2 3 [/SUP], Angie Silva Pena[SUP] 2 [/SUP], Aditya Garg[SUP] 2 [/SUP], Danlu Wu[SUP] 2 [/SUP], Shannon I Phan[SUP] 2 [/SUP], Christopher M Weiss[SUP] 2 [/SUP], Xing Cheng[SUP] 2 [/SUP], Jack Greenhouse[SUP] 4 [/SUP], Tatyana Orekov[SUP] 4 [/SUP], Daniel Valentin[SUP] 4 [/SUP], Swagata Kar[SUP] 4 [/SUP], Laurent Pessaint[SUP] 4 [/SUP], Hanne Andersen[SUP] 4 [/SUP], Christopher C Stobart[SUP] 5 [/SUP], Melissa H Bloodworth[SUP] 6 [/SUP], R Stokes Peebles[SUP] 6 7 [/SUP], Yang Liu[SUP] 8 [/SUP], Xuping Xie[SUP] 8 [/SUP], Pei-Yong Shi[SUP] 8 [/SUP], Martin L Moore[SUP] 2 [/SUP], Roderick S Tang[SUP] 2 [/SUP]
Affiliations
- PMID: 35906244
- DOI: 10.1038/s41541-022-00509-6
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine.